Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CEO Vounatsos, Aduhelm Commercial Team To Exit As Biogen Shifts Focus

More Jobs, Cost Cuts Bring Year’s Total To $1bn

Executive Summary

The company will prioritize later-stage R&D, including potential accelerated approval for a second anti-amyloid antibody, while replacing its CEO and cutting Aduhelm commercial operations and other costs.

You may also be interested in...



Biogen Closes The Book On The Aduhelm Saga

Biogen will end the development and commercialization of Aduhelm, the first anti-amyloid antibody drug to reach the US market for Alzheimer’s, including the confirmatory ENVISION trial.

Biogen Closes The Book On The Aduhelm Saga

Biogen will end the development and commercialization of Aduhelm, the first anti-amyloid antibody drug to reach the US market for Alzheimer’s, including the confirmatory ENVISION trial. Product’s legacy includes an FDA that appears less enthusiastic about accelerated approvals for large indications and a CMS that is more interested in label-driven reimbursement decisions.

Biogen CEO Plots A Slow Return To Growth As Revenue Set To Shrink Again In 2023

Christopher Viehbacher told his first earnings call as CEO that a review is under way to reverse Biogen’s fortunes, but noted Leqembi will not be a meaningful contributor while treatment and reimbursement bottlenecks remain.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146320

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel